References of "Legrand, Victor"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailHigh Prevalence of Abdominal Aortic Aneurysm in Patients with Three-vessel Coronary Artery Disease.
Durieux, R.; VAN DAMME, Hendrik ULg; Labropoulos, N. et al

in European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery (2014)

OBJECTIVES: Currently, the prevalence of abdominal aortic aneurysm (AAA) in patients with coronary artery disease (CAD) and the correlation between CAD severity and AAA prevalence are not clearly known ... [more ▼]

OBJECTIVES: Currently, the prevalence of abdominal aortic aneurysm (AAA) in patients with coronary artery disease (CAD) and the correlation between CAD severity and AAA prevalence are not clearly known. We conducted a prospective study to determine the prevalence of AAA in patients undergoing coronary angiography and to determine the risk factors and a coronary profile associated with AAA. METHODS: Over an 18-month period, abdominal aortic ultrasound was performed on 1,000 patients undergoing coronary angiography for suspected or known CAD, or prior to valve surgery. Clinical characteristics and coronary profile were collected from the patients. RESULTS: The overall number of previously repaired, already diagnosed, and new cases of AAA in the study population was 42, yielding a prevalence of 4.2%. Among the patients with newly detected AAAs, only two had an AAA diameter of >54 mm and were therefore treated surgically. In men aged >/=65 years, the prevalence reached 8.6%, while in men with three-vessel CAD it was 14.4%. Multivariate analysis showed that age >/=65 years (p = .003), male gender (p = .003), family history of AAA (p = .01), current smoking (p = .002), and three-vessel CAD (p < .001) were significantly associated with a higher prevalence of AAA. CONCLUSION: The prevalence of AAA was high in men aged >/=65 years and in those with three-vessel CAD regardless of age. While our findings do not prove the cost-effectiveness of screening for AAA in these high risk patients, they do support the usefulness of a quick ultrasound examination of the abdominal aorta during routine transthoracic echocardiography in such patients. [less ▲]

Detailed reference viewed: 13 (7 ULg)
Full Text
Peer Reviewed
See detailNew Insights Into Aortic Diseases A Report From the Third International Meeting on Aortic Diseases (IMAD3)
KUIVANIEMI, Helena; SAKALIHASAN, Natzi ULg; LEDERLE, Franck et al

in AORTA (2013), 1

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailIdentification of protein biomarkers associated with cardiac ischemia by a proteomic approach.
Fillet, Marianne ULg; Deroyer, Céline ULg; COBRAIVILLE, G. et al

in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2013), 18(7), 614-24

Angina is chest pain induced by ischemia of the heart muscle, generally due to obstruction or spasm of the coronary arteries. People that suffer from average to severe cases of angina have an increased ... [more ▼]

Angina is chest pain induced by ischemia of the heart muscle, generally due to obstruction or spasm of the coronary arteries. People that suffer from average to severe cases of angina have an increased percentage of death before the age of 55, usually around 60%. Therefore, prevention of major complications, optimizing diagnosis, prognosis and therapeutics are of primary importance. The main objective of this study was to uncover biomarkers by comparing serum protein profiles of patients suffering from stable or unstable angina and controls. We identified by non-targeted proteomic approach and confirmed by the means of independent techniques, the differential expression of several proteins indicating significantly increased vascular inflammation response, disturbance in the lipid metabolism and in atherogenic plaques stability. [less ▲]

Detailed reference viewed: 14 (4 ULg)
Full Text
Peer Reviewed
See detailL'imagerie cardiovasculaire multimodalites avant l'implantation d'une prothese valvulaire aortique par voie percutanee.
DAVIN, Laurent ULg; BRUYERE, Pierre-Julien ULg; LANCELLOTTI, Patrizio ULg et al

in Revue Médicale de Liège (2013), 68(2), 86-93

Calcified aortic valve stenosis is the most frequent valvular heart disease in developed countries with a very poor outcome when symptoms develop. However, several of these patients are denied for surgery ... [more ▼]

Calcified aortic valve stenosis is the most frequent valvular heart disease in developed countries with a very poor outcome when symptoms develop. However, several of these patients are denied for surgery. The main reasons are their advanced age (elderly patient), co-morbidities, technical limitations and a very high surgical risk. It is currently possible to propose a Transcatheter Aortic Valve Implantation (TAVI). After selection of candidates, the feasibility of the intervention is analysed. The size of the aortic bioprosthesis must be selected according to the cardiac anatomy. Several cardiac imaging modalities (echocardiography, computed tomography and cardiac MRI) can be used to identify unsuitable situations. Heavy calcifications or tortuosity can thwart the retrograde approach use. The sub-clavian arteries (for the CoreValve) and trans-apical approach (for the Edwards-Sapien) constitute alternatives ways. [less ▲]

Detailed reference viewed: 29 (5 ULg)
Full Text
Peer Reviewed
See detailSubacute Transcatheter CoreValve Thrombotic Obstruction.
LANCELLOTTI, Patrizio ULg; Radermecker, Marc ULg; Weisz, Sara H et al

in Circulation: Cardiovascular Interventions (2013), 6(3), 32-3

Detailed reference viewed: 16 (1 ULg)
Full Text
See detailNursing care after Transcatheter Aortic Valve Implantation with the Medtronic CoreValve Revalving® system
ERPICUM, Marie ULg; RADERMECKER, Marc ULg; DEFRAIGNE, Jean ULg et al

Poster (2011, April 02)

The risks, complications and results of the transcatheter aortic valve implantation (TAVI) are widely described. But to our knowledge, no one has yet defined the nursing cares required after this ... [more ▼]

The risks, complications and results of the transcatheter aortic valve implantation (TAVI) are widely described. But to our knowledge, no one has yet defined the nursing cares required after this procedure and their effects on the TAVI results. The aims of this review are to describe the nursing cares required after TAVI and to determine which aspects of the management could be optimized to improve the results of the procedure. [less ▲]

Detailed reference viewed: 169 (9 ULg)
Full Text
Peer Reviewed
See detailOptions interventionnelles en matiere de traitement moderne de la cardiomyopathie hypertrophique obstructive.
Dulguerov, F.; RADERMECKER, Marc ULg; Legrand, Victor ULg

in Revue Médicale de Liège (2011), 66(1), 13-7

Obstructive hypertrophic cardiomyopathy is a complex pathology. The understanding of its physiopathology and, notably, of the SAM phenomenon (Systolic Anterior Motion), is crucial for all available ... [more ▼]

Obstructive hypertrophic cardiomyopathy is a complex pathology. The understanding of its physiopathology and, notably, of the SAM phenomenon (Systolic Anterior Motion), is crucial for all available treatments. Amongst the most efficient therapies, one can cite the septal myectomy and its most recent technical updates, as well as the alcohol septal ablation. The choice between these two methods depends on the general state of the patient, the thickness of the interventricular septum and the coronary anatomy of the patients. [less ▲]

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailClinical significance of active myeloperoxidase in carotid atherosclerotic plaques
GACH, Olivier ULg; Magne, Julien ULg; Franck, Thierry ULg et al

in International Journal of Cardiology (2011), 152(1), 149-151

Detailed reference viewed: 37 (15 ULg)
Full Text
Peer Reviewed
See detailOptions interventionnelles en matière de traitement moderne de la cardiomyopathie hypertrophique obstructive
DULGUEROV, Filip ULg; RADERMECKER, Marc ULg; LEGRAND, Victor ULg

in Revue Médicale de Liège (2011), 66(1), 13-7

Obstructive hypertrophic cardiomyopathy is a complex pathology. The understanding of its physiopathology and, notably, of the SAM phenomenon (Systolic Anterior Motion), is crucial for all available ... [more ▼]

Obstructive hypertrophic cardiomyopathy is a complex pathology. The understanding of its physiopathology and, notably, of the SAM phenomenon (Systolic Anterior Motion), is crucial for all available treatments. Amongst the most efficient therapies, one can cite the septal myectomy and its most recent technical updates, as well as the alcohol septal ablation. The choice between these two methods depends on the general state of the patient, the thickness of the interventricular septum and the coronary anatomy of the patients. [less ▲]

Detailed reference viewed: 80 (9 ULg)
Full Text
Peer Reviewed
See detailAssessment of high sensitive troponin T and I immunoassays in patients with acute chest
Le Goff, Caroline ULg; Garweg, Christophe ULg; Laurent, Terry et al

in Clinical Chemistry (2010, July), 56(S6), 127

Introduction: Cardiac troponin I and T are specific markers of myocardial injury that are widely used for the diagnosis of acute coronary syndrome (ACS). In acute chest pain without ST-segment elevation ... [more ▼]

Introduction: Cardiac troponin I and T are specific markers of myocardial injury that are widely used for the diagnosis of acute coronary syndrome (ACS). In acute chest pain without ST-segment elevation, they are used to differentiate unstable angina from non ST-segment elevation myocardial infarction (NSTEMI). Recently, troponin assays with higher analytical sensitivities became available to enable the detection of minor myocardial damage and identify individuals at higher risk for ACS. As a result of its high tissue-specificity, cardiac troponin T and I are cardio-specific, highly sensitive markers for myocardial damage. The aim of this study was to evaluate the new higher sensitive troponin (T and I) in patients with stable angina and acute chest pain without ST-segment elevation. Methods: Sixty subjects (mean age : 65.5± 11 years), were included: 20 healthy controls, 20 patients with stable angina, 9 with unstable angina (troponin-) and 18 patients with NSTEMI myocardial infarction (troponin+). The protocol was approved by the ethic committee of the University of Liège (Belgium). High sensitive troponin T (hsTnT) determination was realized on heparin plasma by electrochemiluminescence immunoassay on Modular E (Roche Diagnostic). Troponin I II (TnI II) is a chemiluminescent microparticle immunoassay for the quantitative determination of cardiac troponin-I in heparine plasma on the ARCHITECT i System (Abbott Diagnostic). The lower detection limit of these assays was 0.005μg/L for hsTnT and 0.01μg/L for TnI II. Stastistical analysis was performed using t test. P value <0.05 was considered significant. Results: HsTNT levels were 0.003(0.003, 0.004) [median baseline (1st, 3rd quartile)]ng/ml in controls, 0.0075 (0.00475, 0.014) ng/ml in stable angina, 0.011(0.006, 0.012) ng/ml in unstable angina and 0.3715 (0.1795, 1.00725) ng/ml in NSTEMI ACS. TnI II levels were 0 (0, 0.001) ng/ml in controls and in patients with stable angina, 0.07 (0.005, 0.014) ng/ml in unstable angina and 1.4475 (0.0407, 2.656) ng/ml in NSTEMI. HsTNT and TnI II levels were significantly increased in NSTEMI as compared to control subjects, patients with stable and unstable angina. TnI II levels were also increased in unstable angina as compared to controls. Conclusion: In our population, TnI II was more sensitive than hsTNT to detect minor myocardial damage in patients with unstable angina as compared to controls. Therefore, future studies will have to determine whether TnI II might contribute to better risk stratification and treatment strategy in this group of patients. [less ▲]

Detailed reference viewed: 122 (16 ULg)
Full Text
See detailValve aortique percutanée
ERPICUM, Marie ULg; DEFRAIGNE, Jean ULg; LANCELLOTTI, Patrizio ULg et al

in Urgences & Accueil (2010), 11(40), 6-8

Transcatheter aortic valve implantation (TAVI) is increasingly performed and represents a relatively safe alternative treatment for high risk patients denied to surgical aortic valve replacement. TAVI is ... [more ▼]

Transcatheter aortic valve implantation (TAVI) is increasingly performed and represents a relatively safe alternative treatment for high risk patients denied to surgical aortic valve replacement. TAVI is performed at the University Hospital of Liege since July 2008 with the Medtronic CoreValve Revalving® system by femoral or subclavian access. This paper exposed the technique of TAVI and the nursing care required after this procedure. [less ▲]

Detailed reference viewed: 66 (14 ULg)
Full Text
Peer Reviewed
See detailTraitement percutané d’une cardiomyopathie hypertrophique obstructive
Moonen, Marie ULg; Legrand, Victor ULg; Lancellotti, Patrizio ULg et al

in Revue Médicale de Liège (2009), 64(10), 481

Detailed reference viewed: 49 (2 ULg)
Full Text
Peer Reviewed
See detailPercutaneous transvenous mitral annuloplasty: initial human experience with a novel coronary sinus implant device.
Sack, S.; Kahlert, P.; Bilodeau, L. et al

in Circulation Cardiovascular Interventions (2009), 2(4), 277-84

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailBaseline inflammation is not predictive of periprocedural troponin elevation after elective percutaneous coronary intervention.
Gach, Olivier ULg; Louis, Olivier ULg; Chapelle, Jean-Paul ULg et al

in Heart & Vessels (2009), 24(4), 267-70

High-sensitivity C-reactive protein predicts future cardiovascular events in both healthy individuals and patients with unstable and stable coronary syndromes. Few data are available about the incidence ... [more ▼]

High-sensitivity C-reactive protein predicts future cardiovascular events in both healthy individuals and patients with unstable and stable coronary syndromes. Few data are available about the incidence and the relation to inflammation of troponin elevation following percutaneous coronary intervention (PCI), a potential predictor of longterm outcome. We sought to confirm the impact of embolization on long-term outcome and evaluate the ability of baseline inflammation to predict troponin elevation induced by PCI. We prospectively analyzed 200 patients treated by PCI for stable or Braunwald IIA class unstable angina. The patients were recruited between January 1997 and May 1999, and the population was followed during a mean follow-up of 32 months. Major adverse cardiac events (MACEs) were defined as the occurrence of death, myocardial infarction or recurrent angina requiring repeat PCI, or coronary artery bypass grafting. During the follow-up period, 58 MACEs were observed. By multivariate analysis, independent predictors for the occurrence of MACEs were unstable angina and troponin I level after PCI (P < 0.0001 for both). No correlation was found between baseline inflammation and significant troponin I elevation post PCI and by multivariate analysis, no biological variable was a predictor of troponin I elevation post PCI. Baseline inflammation cannot predict onset of minor myonecrosis damage (expressed by troponin elevation) induced by PCI, a significant predictor of long-term outcome in this setting. [less ▲]

Detailed reference viewed: 21 (7 ULg)
Full Text
Peer Reviewed
See detailBelgian Society of Cardiology position paper on heart centres in Belgium.
Berkenboom, Guy; Budts, Werner; Claeys, Marc et al

in Acta Cardiologica (2009), 64(4), 537-9

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailPrévention de la resténose et des accidents cardiaques après angioplastie coronaire chez le diabétique
Nyssen, Astrid; Legrand, Victor ULg; Scheen, André ULg

in Revue Médicale de la Suisse Romande (2009), 5

Différentes approches pharmacologiques systémiques ont été testées pour réduire le risque de resténose et de complications après angioplastie coronaire, avec ou sans stent, objectif prioritaire dans la ... [more ▼]

Différentes approches pharmacologiques systémiques ont été testées pour réduire le risque de resténose et de complications après angioplastie coronaire, avec ou sans stent, objectif prioritaire dans la population diabétique où ce risque est significativement accru. Le but de cet article est de décrire les effets des principales classes médicamenteuses évaluées quant au risque de resténose, à la nécessité de recourir à de nouvelles procédures de revascularisation et à l’incidence des événements cardiaques majeurs (décès, infarctus non mortels et revascularisations). Nous analyserons le rôle des antiagrégants plaquettaires, des acides gras oméga 3, des statines, des anti-inflammatoires, des immunomodulateurs, des anti-oxydants et des inhibiteurs du système rénine-angiotensine. Dans toute la mesure du possible, nous centrerons notre atten tion sur les résultats obtenus dans la population diabétique. [less ▲]

Detailed reference viewed: 99 (4 ULg)
Full Text
Peer Reviewed
See detailRisque de restenose et d'evenements cardiaques apres angioplastie coronaire chez le patient diabetique: reduction par des approches pharmacologiques systemiques.
Legrand, Victor ULg; Scheen, André ULg; Nyssen, Astrid

in Revue Médicale de Liège (2009), 64(4), 192-8

Various systemic pharmacological approaches have been evaluated to reduce the risk of restenosis after coronary angioplasty, with or without stent, in the general population and in diabetic patients who ... [more ▼]

Various systemic pharmacological approaches have been evaluated to reduce the risk of restenosis after coronary angioplasty, with or without stent, in the general population and in diabetic patients who are at increased risk for such complication. The aim of the present paper is to describe the effects of the main pharmacological classes on the risk of restenosis, the need for new revascularisation procedures and the incidence of major clinical events (MACE: death, myocardial infarction, revascularisation). We will analyse the role of antiplatelet agents, omega-3 fatty acids, statins, anti-inflammatory compounds, immunomodulators, anti-oxidants, glitazones and, finally, classical antidiabetic drugs such as metformin and insulin. Whenever possible, we will focus our attention on the results obtained in the diabetic population. [less ▲]

Detailed reference viewed: 80 (5 ULg)
Full Text
Peer Reviewed
See detailRapport benefice/risque des endoprotheses coronaires pharmaco-actives. 2ème partie : analyse dans la population diabétique
Nyssen, Astrid ULg; Legrand, Victor ULg; Scheen, André ULg

in Revue Médicale de Liège (2008), 63(11), 654-661

The diabetic patient is at high risk of coronary heart disease. He/she can benefit of revascularisation procedures, even if he/she is exposed to a higher incidence of complications after a coronary artery ... [more ▼]

The diabetic patient is at high risk of coronary heart disease. He/she can benefit of revascularisation procedures, even if he/she is exposed to a higher incidence of complications after a coronary artery bypass graft or a percutaneous transluminal coronary angioplasty. The use of drug-eluting stents — paclitaxel (PES) or sirolimus (SES) — dramatically reduces the risk of restenosis as compared to bare-metal stents; nevertheless, the rate of restenosis remains almost double in diabetic patients compared to that observed in non-diabetic subjects. However, the risk of (very) late thrombosis is higher with drug-eluting stents than with bare-metal stents, in the diabetic population as in the non-diabetic population. Altogether, among diabetic patients, the incidence of major cardiovascular events is significantly reduced with drug-eluting stents. This global clinical benefit essentially results from a diminution of revascularisation procedures rather than from a reduction of myocardial infarcts or cardiovascular deaths. Comparison between SES and PES gives discordant results. Indeed, while the loss of intra-stent lumen is more important with PES than with SES, PES are associated with a lower rate of major cardiovascular events than SES. Efficacious antiplatelet therapy in the long run is mandatory in all diabetic patients treated with drug-eluting stents [less ▲]

Detailed reference viewed: 43 (4 ULg)